NDA 209570 · Chemo Research Sl
Benznidazole
Benznidazole · Oral
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 15, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 29, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
7 Phase 3, 2 recruiting
FAERS reports
102
58 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2026.
Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi . This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi ( 1 ). This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials ( 1 , 14 ).
Mechanism: Benznidazole is a nitroimidazole antimicrobial drug [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 29, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
2 products under this application
- BENZNIDAZOLE · BENZNIDAZOLE 100MG · TABLET, ORAL · Prescription
- BENZNIDAZOLE · BENZNIDAZOLE 12.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Benznidazole" as an intervention, any sponsor and status, largest first.
- BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' DiseasePivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT00123916 · 2,854 participants · Start Nov 2004 · Primary completion Jul 2015
Drug: Benznidazole; Placebo · For: Chagas Disease; Trypanosomiasis; Heart Disease
Sites: Buenos Aires, Argentina; Belen de Escobar, Argentina; Isidro Casanova, Argentina · 47 sites in all
- Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical TrialPivotal-lookingCompleted
Instituto Nacional de Parasitologia Dr. Mario Fatala ChabenGovernment (non-federal)
NCT02386358 · 910 participants · Start Mar 1999 · Primary completion Dec 2012
Drug: Benznidazole; Placebo · For: Chagas Disease
Sites: Ciudad Autónoma de Buenos Aires, Argentina
- CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)Pivotal-lookingStatus unknown
Universidad Autónoma de BucaramangaAcademic, hospital or other
NCT02369978 · 500 participants (planned) · Start Aug 2015 · Primary completion Aug 2018
Drug: Nifurtimox; Benznidazole and 1 more · For: Chagas Disease
Sites: Bucaramanga, Colombia
- New Therapies and Biomarkers for Chagas InfectionPivotal-lookingCompleted
University of Texas, El PasoAcademic, hospital or other
NCT03981523 · 450 participants · Start Dec 18, 2019 · Primary completion May 29, 2024
Drug: Benznidazole; Nifurtimox · For: Trypanosoma Cruzi Infection; Chagas Disease
Sites: Cochabamba, Bolivia; Tarija, Bolivia; Sucre, Bolivia
- Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas DiseasePivotal-lookingRecruiting
Laboratorio Elea Phoenix S.A.Industry
NCT04897516 · 300 participants (planned) · Start Jul 28, 2021 · Primary completion Jun 1, 2026
Drug: Short regimen of benznidazole; Short treatment with benznidazole and 1 more · For: Chagas Disease
Sites: Buenos Aires, Argentina; Corrientes, Argentina; Santiago del Estero, Argentina · 6 sites in all
- Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.Pivotal-lookingCompleted
Hospital Universitari Vall d'Hebron Research InstituteAcademic, hospital or other
NCT03191162 · 238 participants · Start Apr 21, 2017 · Primary completion Sep 21, 2020
Drug: Benznidazole · For: Chagas Disease; Trypanosoma Cruzi Infection
Sites: Buenos Aires, Argentina; Corrientes, Argentina; Belo Horizonte, Brazil · 7 sites in all
- Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas DiseasePivotal-lookingStatus unknown
Drugs for Neglected DiseasesAcademic, hospital or other
NCT01489228 · 230 participants (planned) · Start Jun 2011 · Primary completion Aug 2012
Drug: E1224; Benznidazole and 1 more · For: Chronic Chagas Disease, Indeterminate
Sites: Cochabamba, Bolivia; Tarija, Bolivia
Drugs for Neglected DiseasesAcademic, hospital or other
NCT01678599 · 220 participants · Start Apr 2011 · Primary completion Dec 2012
Drug: Benznidazole · For: Chagas Disease
Sites: Aiquile, Bolivia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use issue20
- intentional product use issue18
- rash18
- american trypanosomiasis16
- nausea10
- drug interaction9
- drug ineffective8
- headache8
- off label use6
- dizziness5
- hepatotoxicity5
- infection reactivation5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 4 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 17 |
| 2019 | 21 |
| 2020 | 7 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 6 |
| 2025 | 15 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.
Saade U, de Boer J, Scandale I, et al. · Nat Commun 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M, Reyes PP, Martinez Garcia M, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.
Wiens MO, Kanters S, Mills E, et al. · Antimicrob Agents Chemother 2016 · Meta-Analysis, Systematic Review
- Population pharmacokinetics of benznidazole in adult patients with Chagas disease.
Soy D, Aldasoro E, Guerrero L, et al. · Antimicrob Agents Chemother 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Direct evidence gap on fixed versus adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: Systematic review and individual patient data meta-analysis.
Ciapponi A, Barreira F, Perelli L, et al. · Trop Med Int Health 2023 · Systematic Review, Meta-Analysis
- Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA).
Assmus F, Cruz C, Watson JA, et al. · PLoS Negl Trop Dis 2025 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Chemo Research Sl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.